Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C21 InvestmentsCXXIF -0.41%37 PB Ratio is 1.01 as of Jul. 22, 2026, which is 27% below its 10-year median of 1.39. GuruFocus rates CXXIF with a GF Score™ of 37/100 and a GF Value™ of $0.28 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, C21 Investments ranks better than 74.05% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-22), C21 Investments's share price is $0.2191. C21 Investments's Book Value per Share for the quarter that ended in Mar. 2026 was $0.22. Hence, C21 Investments's PB Ratio of today is 1.01.
The historical rank and industry rank for C21 Investments's PB Ratio or its related term are showing as below:
CXXIF'
s PB Ratio Range Over the Past 10 Years
Min: 0.54 Med: 1.39 Max: 9.33
Current: 1.04
During the past 13 years, C21 Investments's highest PB Ratio was 9.33. The lowest was 0.54. And the median was 1.39.
CXXIF's PB Ratio is ranked better than 74.05% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs CXXIF: 1.04
During the past 12 months, C21 Investments's average Book Value Per Share Growth Rate was -15.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of C21 Investments was 156.50% per year. The lowest was -46.10% per year. And the median was -9.50% per year.
Back to Basics: PB Ratio
C21 Investments (OTCPK:CXXIF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
C21 Investments PB Ratio Related Terms
C21 Investments PB Ratio Historical Data
* Premium members only.
The historical data trend for C21 Investments's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's PB Ratio distribution charts can be found below:
* The bar in red indicates where C21 Investments's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
C21 Investments's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
C21 Investments (CXXIF) has a PB Ratio of 1.01 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on C21 Investments and its competitors. This is 27% below median its historical median of 1.39. Over the past decade, C21 Investments' PB Ratio has ranged from 0.54 to 9.33. According to the industry distribution chart, C21 Investments ranks #239 out of 921 companies in the Drug Manufacturers industry, placing it in the top 26%.
Is C21 Investments' PB Ratio too high?
C21 Investments' current PB Ratio of 1.01 is 27% below median its 10-year median of 1.39. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 9.33. The Drug Manufacturers industry median PB Ratio is 1.86. C21 Investments' value of 1.01 is 45.7% below this industry median. Based on the distribution chart, C21 Investments ranks #239 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, C21 Investments has a GF Score™ of 37/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #239 out of 921 companies for PB Ratio. This puts C21 Investments in the upper half of its industry. The industry median PB Ratio is 1.86. C21 Investments' value of 1.01 is 45.7% below this benchmark. Historically, C21 Investments' own PB Ratio has ranged from 0.54 to 9.33 over the past decade. While the company's 10-year median is 1.39 vs. the industry median of 1.86, C21 Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current PB Ratio of 1.01 is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current PB Ratio is 1.01, which is 27% below median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.22 — trading 21.8% below its estimated fair value. The current PB Ratio is 1.01, which is 27% below median its 10-year median of 1.39 and 45.7% below the Drug Manufacturers industry median of 1.86. C21 Investments' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For C21 Investments (CXXIF), the current PB Ratio is 1.01 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.22 is trading 21.8% below its estimated GF Value™ of $0.28.
GuruFocus considers C21 Investments to be Modestly Undervalued.
Key valuation signals for CXXIF:
PB Ratio: 1.01 (27% below median its 10-year median of 1.39)
GF Value™: $0.28 vs. price of $0.22 (21.8% below fair value)
Industry Position: 45.7% below the Drug Manufacturers median (#239 of 921)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
37GF Score
Get the complete analysis for CXXIF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
